Alterome Therapeutics raises $132 million in a Series B financing led by Goldman Sachs Alternatives.

Apr 03, 2024•over 1 year ago

Amount Raised

$132 Million

Round Type

series b

San Diego

Investors

Colt VenturesBoxer CapitalVida VenturesNextech InvestOrbimedBlue Owl CapitalDigitalis VenturesDriehaus Capital ManagementInvusCanaan PartnersGoldman Sachs Alternatives

Description

Alterome Therapeutics, Inc. announced the closing of a $132 million Series B financing. The proceeds will be used to support the advancement of multiple wholly-owned pipeline programs into the clinic.

Company Information

Company

Alterome Therapeutics

Location

San Diego, California, United States

About

Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. We are a team with expertise in multiple areas of science and operations, dedicated to co-elevating toward our vision to bring life-changing and life-saving therapies to cancer patients. We believe in our journey, in each other, and in our ability to collaboratively develop therapies that will help end cancers. Thus, we seek the best people for our company and provide the resources they need to grow, develop, and accomplish our collective goals. We are moving forward with humility & empathy, fearlessness & resilience, with a sense of inclusion & belonging, open communication and a deep trust. And…we manage to have a lot of fun along the way!

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends